Conclusion and relevance Considering the positive results obtained so far, the study of HIPEC with CRS in peritoneal carcinoma continues, to evaluate its effectiveness. The role of the pharmacist was important in participating in the multidisciplinary team in terms of eligibility of patients for treatment, to prepare oncological therapies and in processing the evaluation data.

No abstract

No abstract

No abstract

who required restarting anti-CGRP therapy after 12 months of treatment.Electronic medical history was used to record following variables: demographic data (sex, age) and clinical data (migraine type, months without anti-CGRP, biological drug, monthly migraine days (MMD), Headache Impact Test-6 score (HIT-6)) at two visits: before the initial biological treatment (baseline); before resumption of biological treatment.The Shapiro-Wilk normality test and the Student's t-test were used for statistical analysis. Results with p-values <0.05 were considered significant. Results 44 patients were included (13 erenumab, 25 galcanezumab, 6 fremanezumab). 84% (37/44) were women and average age was 49 years . 52% (23/44) were CM and 48% (21/44) high frequency EM (!8 MMD). All patients completed 12 months of anti-CGRP treatment due a good response (!50% MMD reduction).55% (24/44) patients restarted treatment due to clinical worsening. Months without treatment were 6,3 ± 3,0.17% (4/24) patients restarted treatment with a different initial anti-CGRP by medical decision (tolerance or improvement of response).Baseline data were 14,0 ± 4,6 average MMD and 68,3 ± 3,7 on the HIT-6 score and when restarting biological treatment were 12 ± 3,0 and 67,7 ± 6,1, respectively.The reduction the MMD at the time of restarting treatment compared to baseline is statistically significant (p<0,01), while the HIT-6 score not (p>0,05). Conclusion and RelevanceRestart of treatment is not required in all patients. Follow-up of them is necessary to assess the long-term benefit after treatment discontinuation. Despite treatment is restarted, a reduction in MMD compared to baseline is observed.